Back to top

Image: Bigstock

Gilead Sciences Inc.

Read MoreHide Full Article

Gilead’s HIV franchise has been gaining momentum of late. Rapid adoption of TAF-based regimens, representing 42% of total Gilead HIV prescription volume, following the launch of Genvoya and the launches of Odefsey and Descovy in 2016 boosted results. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales.The company saw a significant uptick in PrEP usage in 2017 with an estimated 125,000 patients using Truvada by the end of the first quarter. The company submitted a NDA to the FDA for single tablet regimen for bictegravir. However, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which should impact sales. In addition, the HCV franchise continues to be under competitive and pricing pressure leading to a decline in Harvoni and Sovaldi sales. The company expects that the persistent decline in HCV patients will be the primary factor behind the year-over-year decrease.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Gilead Sciences, Inc. (GILD) - free report >>

Published in